24 May

Prime Nordic has invested in Fluicell, a bioscience company that is shaping the future of cell biology, biomedicine and drug development.

Fluicell is advancing Bioscience to the level of Individual Cells. Fluicell provides easy-to-use microfluidic technologies for life science researchers. Their products enable access to the world of individual cells, by expanding capabilities for localized compound delivery, ion channel screening and bioprinting.

Prime Nordic believes that Fluicell has a very competent and strong management team and a product portfolio with a huge potential.  Prime Nordic has noticed that amongst the shareholders are ALMI, Avanz, Nordnet and Danic, which is an indication of stability.

The Fluicell share is listed on the Nasdaq First North Stock Market under the ticker FLUI

For more information, press only:

Kevin Shinduke Kevin.Shinduke@primenordic.com

* The email will not be published on the website.